

Contents

Foreword	xiv
Acknowledgments	xv
Preface	xvi
Supplements and Resources	xviii
Previous Editions' Reviewers	xx

Part 1: The Basics 1

Chapter 1

General Pharmacologic Principles 3

1.1 Basic Terms	4
1.2 Drug Development	5
1.3 Herbal Supplements (Nutraceuticals)	6
1.4 Drug Information Sources	7
1.5 Interpreting Drug Information	8
1.5a Drug Names	8
1.5b Clinical Pharmacology	9
1.5c Indications and Usage	10
1.5d Contraindications	11
1.5e Drug Interactions	12
1.5f Adverse Drug Reactions	13
1.5g Dosage and Administration	16
1.6 Routes of Administration	16
1.6a Enteral Routes	18
1.6b Parenteral Routes	18
1.6c Other Routes	18
1.7 Pharmacokinetics	20
1.7a Absorption	20
1.7b Distribution	22
1.7c Metabolism	23
1.7d Elimination	24
1.8 Pharmacodynamics	25
1.8a Selectivity	25
1.8b Lock and Key Receptor Theory	26
1.8c Racemic Mixtures	27
1.8d Agonists versus Antagonists	27
1.8e Potency	28

1.8f Tolerance	29
1.8g Half-Life	29
1.8h Poisoning and Toxicity	30

1.9 Pharmacogenomics	30
1.10 Prescription Orders	31
1.11 Commonsense Rules	33

Summary 35

Review Questions 35

Case Study 1–1: Calvin Davis 37

Chapter 2

The Metric System and Drug Dosage Calculations 39

2.1 Exponential Powers of 10	41
2.1a Exponents	41
2.2 Systems of Measurement	42
2.2a United States Customary System	42
2.2b The Metric System	42
2.2c Conversion of Units	45
2.2d Factor-Label Method to Convert between Systems	46
2.3 Drug Dosage Calculations	47
2.3a Solutions	47
2.3b Percentage Solutions	48
2.3c Setting Up Proportions	49
2.3d Ratio Solutions	51
2.3e Drug Orders in Drops	51

Summary 53

Review Questions 53

Chapter 3

Pharmacology of the Autonomic Nervous System 55

- 3.1 Nervous System Divisions 56
 - 3.1a PNS Divisions 57
- 3.2 Nervous System Conduction 61
 - 3.2a Types and Location of Neurotransmitters 62
 - 3.2b Receptors 63
 - 3.2c Receptor Classification 65
- 3.3 ANS Drug Terminology 66
 - 3.3a Direct- and Indirect-Acting Agents 68
 - 3.3b Parasympathomimetics 68
 - 3.3c Parasympatholytics 70
 - 3.3d Sympathomimetics 71
 - 3.3e Sympatholytics 73

Summary 74

Review Questions 74

Case Study 3–1: Maria Ramirez 75

Chapter 4

Medicated Aerosol Treatments 77

- 4.1 Basic Concepts of Medicated Aerosols 78
 - 4.1a What Is Aerosol Therapy? 78
 - 4.1b Advantages and Disadvantages 79
 - 4.1c Technical Background 80
 - 4.1d Aerosol Size Matters 81
 - 4.1e Breathing Pattern 82
 - 4.1f Types of Aerosolized Drugs 83
- 4.2 Aerosol Delivery Devices 84
 - 4.2a Metered-Dose Inhaler 84
 - 4.2b Small-Volume Nebulizer 88
 - 4.2c Other Nebulizer Designs 89
 - 4.2d Continuous Bronchodilator Therapy 90
 - 4.2e Dry Powder Inhaler 90
 - 4.2f Choosing the Appropriate Delivery Device 92
 - 4.2g Aerosol Delivery in Intubated Patients 92
- 4.3 The Future 95

Summary 97

Review Questions 97

Case Study 4–1: Mr. Davidson 98

Part 2: The Specific Drug Categories 99

Chapter 5

Bronchodilators 101

- 5.1 Airway Anatomy and Physiology 102
 - 5.1a Bronchoconstriction versus Bronchospasm 103
- 5.2 Neurological Control of Bronchial Smooth Muscle 105
 - 5.2a Sympathetic Nervous System 105
 - 5.2b Parasympathetic Nervous System 105
 - 5.2c Chemical Mediators of Neural Transmission 106
 - 5.2d Sympathetic Nervous System Receptors 107
 - 5.2e The Sympathetic Nervous System in the Lung 108
- 5.3 Bronchodilators 109
 - 5.3a Sympathomimetic (Adrenergic) Bronchodilators 110
 - 5.3b Mechanism of Action 110
- 5.4 Development of the β -Agonists 111
 - 5.4a Catecholamines 112
 - 5.4b Resorcinols 113
 - 5.4c Saligenins 114
 - 5.4d Side Effects of β -Agonists 117
 - 5.4e Classification by Duration of Action 119
- 5.5 Anticholinergic (Parasympatholytic) Bronchodilators 122
 - 5.5a Mechanism of Action 122
 - 5.5b Atropine Sulfate 124
 - 5.5c Ipratropium Bromide (Atrovent®) 124
 - 5.5d Tiotropium Bromide (Spiriva®) 125
 - 5.5e Monitoring Outcomes of Inhaled Bronchodilator Therapy 127



- 5.6 Methylxanthines 129
 - 5.6a Mechanism of Action 129
 - 5.6b Nonbronchodilating Effects of Theophylline 129
- Summary 131
- Review Questions 131
- Case Study 5–1: A 66-year-old male 133
- Case Study 5–2: A 9-year-old boy 133
- Case Study 5–3: A patient with COPD 133

Chapter 6

Mucokinetics and Surfactants 135

- 6.1 The Mucociliary System 136
 - 6.1a Anatomy and Physiology 136
 - 6.1b Structure and Composition of Mucus 137
- 6.2 Bland Aerosols 141
 - 6.2a Definitions 141
 - 6.2b Delivery Methods 141
 - 6.2c Bland Solutions 143
- 6.3 Mucolytics 145
 - 6.3a Definition 145
 - 6.3b Expectorants 148
 - 6.3c Antitussives/Cough Suppressants 148
 - 6.3d Conclusion 149
- 6.4 Surface-Active Agents 150
 - 6.4a Alveolar Physiology and Surfactant Synthesis 150
 - 6.4b Surfactant Function 151
 - 6.4c Indications for Surfactant Replacement Therapy 154
 - 6.4d Types of Exogenous Surfactants 154
 - 6.4e Therapeutic Approaches 155
 - 6.4f Representative Drugs 155
 - 6.4g General Techniques of Surfactant Administration 156
 - 6.4h Adverse Reactions 157
 - 6.4i Surfactant Administration in Adult Patients 158

Summary 160

Review Questions 160

Case Study 6–1: A COPD patient 162

Case Study 6–2: A baby boy 162

Chapter 7

Anti-inflammatory and Antiasthmatic Agents 163

- 7.1 The Inflammatory Process 164
 - 7.1a The Immune Response 164
 - 7.1b Mast Cell Chemical Mediator Release 165
 - 7.1c Types of Asthma 167
 - 7.1d Phases of the Inflammatory Response 167
- 7.2 Corticosteroids 169
 - 7.2a Corticosteroid Physiology 169
 - 7.2b Hypothalamic-Pituitary-Adrenal Axis 171
 - 7.2c Corticosteroid Mechanism of Action 172
 - 7.2d Corticosteroid Use in Airway Remodeling 172
 - 7.2e Adverse Effects of Corticosteroids 173
 - 7.2f Oral and Parenteral Corticosteroid Administration 174
 - 7.2g Inhaled Corticosteroids 174
 - 7.2h Benefits of Daily Corticosteroid Use 177
 - 7.2i Steroid Dependency 179
- 7.3 Antiasthmatics 179
 - 7.3a Cromolyn Sodium 179
 - 7.3b Dosage Forms 180
 - 7.3c Side Effects 180
- 7.4 Prostaglandins 180
 - 7.4a Physiology 180
- 7.5 Leukotriene Modifiers 181
 - 7.5a Physiology 181
- 7.6 Antiasthmatic Monoclonal Antibody 182
 - 7.6a Physiology 182
- 7.7 Treating Upper Airway Congestion 182
 - 7.7a Allergic Rhinitis 182
 - 7.7b Intranasal Medications 183
 - 7.7c Antihistamines 184
 - 7.7d Decongestants 187

Summary 188

Review Questions 188

Case Study 7–1: A 24-year-old woman 189

Case Study 7–2 : A 40-year-old man 189

Chapter 8

Antimicrobial Agents 191

8.1 General Principles of

Anti-infective Therapy 192

8.1a Terminology 192

8.1b The Infection Process 193

8.1c Empiric Therapy 193

8.1d Classification of Bacteria 194

8.1e Identification of Pathogenic Organisms 195

8.1f Mechanisms of Resistance 198

8.1g Monitoring Anti-infective Therapy 199

8.2 Classification of Antibacterial Agents 200

8.2a Bacteriostatic versus Bactericidal 200

8.2b Broad-Spectrum versus Narrow-Spectrum 200

8.2c Based on Mechanism of Action 200

8.2d Antibacterial Agents 201

8.3 Antivirals 209

8.3a Antivirals to Treat Herpes 210

8.3b Antivirals to Treat Respiratory Syncytial Virus 211

8.3c Antivirals to Treat Acquired Immunodeficiency Syndrome (AIDS) 212

8.4 Antifungals 213

Summary 215

Review Questions 215

Case Study 8–1: A 68-year-old man 216

Case Study 8–2: A 47-year-old woman 216

Chapter 9

Cardiac Agents 217

9.1 Cardiovascular Overview 219

9.1a Basic Terminology 219

9.1b Cardiac Circulation 219

9.1c Cardiac Conduction 220

9.1d Ion Influence 222

9.1e The ECG Tracing 223

9.1f Arrhythmias 224

9.1g Sites of Arrhythmias 225

9.2 Antiarrhythmic Agents 225

9.2a Therapeutic Goals 225

9.2b Mechanism of Action 225

9.2c Classification of Antiarrhythmic Drugs 225

9.3 Heart Failure 227

9.3a Pathophysiology 227

9.3b Drugs to Treat Heart Failure 228

9.3c Digoxin for Heart Failure 229

9.3d ACE Inhibitors for Heart Failure 229

9.3e ARBs for Heart Failure 229

9.3f Angiotensin Receptor Neprilysin Inhibitor 230

9.3g β -Antagonists for Heart Failure 230

9.3h Vasodilators for Heart Failure 230

9.3i Diuretics for Heart Failure 231

9.3j Aldosterone Antagonists for Heart Failure 232

9.3k Intravenous Inotropes for Heart Failure 232

9.3l Dopamine for Heart Failure 232

9.3m Nitroprusside for Heart Failure 232

9.3n Nitroglycerin for Heart Failure 233

9.3o Nesiritide for Heart Failure 233

9.4 Management of Shock 233

9.5 Angina 234

9.5a Pathophysiology of Angina 234

9.5b Pharmacologic Treatment of Angina 234

9.5c β -Blockers as Antianginals 234

9.5d Calcium Channel Blockers as Antianginals 236

9.5e Nitroglycerin as an Antianginal 237

9.5f Ranolazine 237

9.6 Acute Coronary Syndromes 238

9.6a Myocardial Infarction 238

9.6b Diabetes Mellitus 238



9.6c Classes of Diabetes Drugs 239

9.6d Lipid-Lowering Agents 240

Summary 242

Review Questions 242

Case Study 9–1: An elderly female 243

Chapter 10

Blood Pressure and Antithrombotic Agents 245

10.1 Blood Pressure 246

10.1a The Basics 246

10.1b Blood Vessels 247

10.1c Regulation of Blood
Pressure 248

10.1d Hypertension 248

10.2 Categories of Drugs to Treat
Hypertension 252

10.2a Direct-Acting α_2 -Agonists
or Central-Acting
Sympatholytics 252

10.2b α_1 -Blockers or Peripheral-
Acting Sympatholytics 253

10.2c β -Blockers 253

10.2d Diuretics 254

10.2e Angiotensin-Converting Enzyme
Inhibitors (ACEIs) 257

10.2f Angiotensin II Receptor
Blockers (ARBs) 258

10.2g Calcium Channel Blockers 259

10.2h Vasodilators 259

10.2i Agents for Hypertensive
Emergencies/Urgencies 260

10.2j Treating Hypotension 264

10.3 The Hemostatic System 264

10.3a The Clotting Process 264

10.3b Anticoagulants 265

10.3c Direct Thrombin Inhibitors 268

10.3d Antiplatelet Drugs 269

10.3e Platelet Glycoprotein IIb/IIIa
Receptor Inhibitors 271

10.3f Fibrinolytics 271

Summary 273

Review Questions 273

**Case Study 10–1: Hypertensive
emergency** 274

Case Study 10–2: Antiplatelet therapy 274

Chapter 11

Neuromuscular, Sedative, Anesthetic, and Analgesic Agents 275

11.1 Nerve Transmission 277

11.1a Physiology of Muscle
Contraction 277

11.1b Acetylcholinesterase 278

11.1c Neuromuscular Blocking
Agents 278

11.1d Nondepolarizing Agents 279

11.1e Depolarizing Agents 279

11.1f NMBA Selection Factors 280

11.2 Skeletal Muscle Relaxants 283

11.3 Sedatives, Hypnotics, and
Anxiolytics 284

11.3a Terminology 284

11.3b Benzodiazepines 284

11.3c α_2 -Adrenergic Agonist
(Sedative) 285

11.3d Nonbenzodiazepines 285

11.3e Barbiturates 285

11.3f Conscious Sedation 286

11.4 Anesthetics 286

11.4a General versus Local 286

11.4b General Anesthesia 286

11.4c Stages of Anesthesia 287

11.4d Specific General Anesthetics 287

11.4e Local Anesthetics 289

11.4f Postoperative Nausea
and Vomiting 290

11.5 Ventilatory Stimulants 291

11.6 Analgesia 292

11.6a Principles of Analgesia 292

11.6b The Pain Response 292

11.6c Analgesics 293

11.6d Outcomes Assessment
Analgesic Therapy 294

11.6e Pain-Related Terminology 294

11.6f Classes of Analgesics 295

11.6g Opioids 295

- 11.6h Opioid Antagonists 297
- 11.6i Corticosteroids 298
- 11.6j Nonsteroidal Anti-inflammatory Agents 299
- 11.6k Analgesic Synergy 300
- 11.6l Adjuncts to Analgesics 301

Summary 303

Review Questions 303

Case Study 11–1: A 38-year-old man 304

Chapter 12

Therapeutic Medical Gases 305

- 12.1 Oxygen Therapy 306
 - 12.1a Physiologic Background 306
 - 12.1b Hypoxemia 307
 - 12.1c Clinical Manifestations of Hypoxemia 309
 - 12.1d Hypoxia 309
 - 12.1e Goals of Oxygen Therapy 311
 - 12.1f Oxygen Administration Devices 311
 - 12.1g Monitoring Oxygen Therapy 316
 - 12.1h Hazards of Oxygen Therapy 317
- 12.2 Helium Therapy 318
 - 12.2a Indications for Helium Therapy 318
 - 12.2b Administration of Helium-Oxygen 319
 - 12.2c Hazard of Helium-Oxygen Therapy 319
- 12.3 Nitric Oxide Therapy 319
 - 12.3a Physiology of Nitric Oxide 320
 - 12.3b iNO Administration and Dosage 320
 - 12.3c Therapeutic Indications for Inhalation of Nitric Oxide 321
 - 12.3d Monitoring Nitric Oxide Therapy 321

Summary 322

Review Questions 322

Case Study 12–1: A 68-year-old woman 323

Part 3: Putting It All Together 325

Chapter 13

Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema 327

- 13.1 Asthma 329
 - 13.1a Background 329
 - 13.1b Differential Diagnosis 330
 - 13.1c Asthma Symptoms 331
 - 13.1d Asthma Treatment Goals 333
 - 13.1e Classification of Asthma Severity 334
 - 13.1f Asthma Medications 335
 - 13.1g Asthma Management 337
 - 13.1h Management of Acute Asthma Exacerbations 339
- 13.2 COPD 343
 - 13.2a Background 343
 - 13.2b Etiology 343
 - 13.2c Prevention: The Key to Treatment of COPD 345
 - 13.2d COPD Treatment Goals 350
 - 13.2e Assessment of COPD 350
 - 13.2f Drugs Used to Treat COPD 351
 - 13.2g Step-by-Step Approach 355

Summary 357

Review Questions 357

Case Study 13–1: A 25-year-old man 358

Chapter 14

Pharmacologic Treatment of Respiratory Infectious Diseases 359

- 14.1 Developing a Therapeutic Plan for Respiratory Infectious Diseases 361
 - 14.1a Empiric Treatment 361
 - 14.1b Local Resistance Patterns (the Antibigram) 362
 - 14.1c Individualizing Therapy 363
- 14.2 Upper Airway Infectious Diseases 365
 - 14.2a Otitis Media 365



14.2b Sinusitis	368
14.2c Pharyngitis	371
14.3 Other Upper Airway Infections	373
14.3a Epiglottitis	373
14.3b Croup	374
14.4 Lower Respiratory Tract Infections	375
14.4a Acute Bronchitis and Bronchiolitis	375
14.4b Pneumonia	377
14.4c Tuberculosis	384
14.4d Avian Influenza	386
14.4e COVID-19	386
14.5 Chemical Terrorism	388
Summary	389
Review Questions	389
Case Study 14–1: A 60-year-old man	390

Chapter 15

Medications for Emergency Cardiovascular Life Support 391

15.1 Normal Conduction and Arrhythmias	393
15.1a Electrophysiology	393
15.1b Normal Conduction	394
15.1c Acute Myocardial Infarction	395
15.1d Bradycardia	396
15.1e Tachycardia	396
15.1f Ventricular Fibrillation	398
15.1g Asystole	399
15.1h Pulseless Electrical Activity	399
15.2 Pharmacologic Agents for Advanced Life Support	400
15.2a Medication Access	400
15.2b Categories of ACLS Drugs	400
15.3 Medications for Cardiovascular Support	401
15.3a Oxygen	401
15.3b Epinephrine	402
15.3c Vasopressin	403
15.3d Norepinephrine	403
15.3e Sodium Bicarbonate	404

15.4 Positive Inotropic Drugs	405
15.4a Digoxin	405
15.4b Milrinone	405
15.4c Dopamine	406
15.4d Dobutamine (Dobutrex®)	406
15.5 Antiarrhythmic Drugs	407
15.5a Atropine	407
15.5b Amiodarone (Cordarone®)	408
15.5c Lidocaine	408
15.5d Procainamide (Pronestyl®)	409
15.5e Magnesium Sulfate	410
15.5f Ibutilide (Corvert®)	411
15.6 Calcium Channel Blockers	411
15.6a Verapamil (Calan®, Isoptin®)	411
15.6b Diltiazem (Cardizem®)	412
15.6c Adenosine (Adenocard®)	412
15.6d β -Adrenergic Blockers	413
15.6e Sotalol (Betapace®)	414

Review Questions 415

Case Study 15–1: A 67-year-old woman 416

Appendices 417

Glossary 421

Index 429